Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 501, Issue 1-2, Pages 199-210Publisher
ELSEVIER
DOI: 10.1016/j.ijpharm.2016.01.080
Keywords
Rosuvastatin; Pulmonary delivery; Nanostructured lipid carrier; Dry powder for inhalation
Categories
Ask authors/readers for more resources
Rosuvastatin (RSVS), an anti-lipidemic agent suggested for the treatment of airway remodeling in chronic obstructive pulmonary disease (COPD). It shows a pleiotropic effect on airway smooth muscles and inhibits proliferative activities of physiological mitogens. The aim of the present study was to develop and investigate the targeting potential of rosuvastatin (RSVS) to lung as loaded in nanostructured lipid carrier dry powder for inhalation (RNLC-DPI). RNLC dispersion was converted into respirable particle by lyophilization using 5% mannitol as cryoprotectant-carrier. Targeting efficiency of RNLC-DPI was evaluated in vitro for aerosol performance using 8-stage cascade impactor as well in vivo in Wistar rats for pulmokinetics. In vitro aerosol performance demonstrated mass median aerodynamic diameter of < 3 mu m with fine particle fraction of > 90% at 60 L/min. Improved aerosol performance was observed for RNLC-DPI prepared using L-leucin as anti-static agent. Modified in vivo performance with higher Cmax (1.14-fold), improvement in t(1/2) (5-fold) and 35-fold improvement in AUC(0-infinity) indicated significant improvement in bioavailability of RNLC-DPI. Lipidic nature and smaller size of particles helped in bypassing macrophage clearance leading to higher targeting factor. Thus, study demonstrated potential of RNLC-DPI for lung targeting and further for COPD treatment. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available